Professor Shen Lin: Gastrointestinal Oncology Expert at Peking University Cancer Hospital

Professor Shen Lin: Gastrointestinal Oncology Expert at Peking University Cancer Hospital

Professor Shen Lin: Precision Treatment for Gastrointestinal Cancer

Professor Shen Lin is a senior medical oncologist, professor, and doctoral supervisor at Peking University Cancer Hospital. She is internationally recognized for clinical research and treatment development in gastric cancer, esophageal cancer, colorectal cancer, and other gastrointestinal malignancies.

Her work focuses on molecular classification, targeted therapy, immunotherapy, biomarker-guided treatment, multidisciplinary care, and early-phase to late-phase clinical trials.

For an overview of the hospital, see our Peking University Cancer Hospital international patient guide. Patients researching gastric cancer surgery can also read our profile of Professor Ji Jiafu.

Clinical and Academic Focus

Professor Shen’s principal areas include:

  • advanced and recurrent gastric cancer;
  • gastroesophageal junction cancer;
  • esophageal cancer;
  • colorectal cancer;
  • rare gastrointestinal tumors;
  • targeted therapy and immunotherapy;
  • molecular and biomarker-guided treatment;
  • clinical-trial evaluation; and
  • second opinions after resistance to standard therapy.

Advanced Gastric Cancer

Advanced gastric cancer may involve distant lymph nodes, the liver, peritoneum, lungs, bone, or other sites. Treatment usually relies on systemic therapy, with surgery or local treatment reserved for selected circumstances.

First-line and later treatment choices depend on previous therapy, performance status, organ function, tumor burden, symptoms, and biomarkers. Options may include chemotherapy, targeted therapy, immunotherapy, antibody-drug conjugates, or clinical trials.

Professor Shen has led and participated in major trials intended to define more effective treatment combinations for molecularly selected patients.

Gastroesophageal Junction and Esophageal Cancer

Tumors near the junction of the esophagus and stomach can have features of both diseases. Treatment planning may involve medical oncology, surgery, radiation oncology, gastroenterology, radiology, pathology, and nutrition.

For locally advanced disease, treatment can include chemotherapy, chemoradiotherapy, surgery, immunotherapy, or a planned sequence. For metastatic disease, histology and biomarkers guide systemic treatment.

Colorectal Cancer

Metastatic colorectal cancer is biologically diverse. Molecular testing commonly includes RAS, BRAF, mismatch repair or microsatellite instability, and selected additional targets. Tumor location and previous treatment also influence therapy.

Some patients with liver- or lung-limited metastases may benefit from a multidisciplinary approach that includes surgery, ablation, radiation, or other local treatment in addition to systemic therapy.

A tumor initially considered unresectable may occasionally become operable after effective treatment, but this requires specialist review and cannot be guaranteed.

Biomarker Testing

Biomarkers can help predict whether a tumor may respond to a targeted or immune treatment. Depending on the cancer type, testing may include:

  • HER2;
  • PD-L1;
  • mismatch repair or microsatellite instability;
  • CLDN18.2;
  • FGFR2 alterations;
  • EBV-related features;
  • RAS and BRAF;
  • NTRK, RET, or other uncommon alterations; and
  • broad next-generation sequencing in selected cases.

Test quality, specimen age, tumor content, scoring method, and treatment setting all matter. A positive biomarker does not guarantee response, and a negative result may need review if the sample is inadequate.

Immunotherapy

Immune checkpoint inhibitors can provide meaningful benefit for selected gastrointestinal cancers, particularly when supported by biomarkers or trial evidence. They can also cause immune-related inflammation of the lungs, liver, bowel, endocrine glands, skin, heart, nervous system, or other organs.

New diarrhea, jaundice, severe fatigue, breathing difficulty, chest pain, weakness, or hormonal symptoms during immunotherapy requires prompt medical assessment. Patients should not manage suspected immune toxicity alone.

Targeted Therapy and Antibody-Drug Conjugates

Targeted medicines act on specific proteins or pathways involved in cancer growth. Antibody-drug conjugates combine a targeting antibody with a cell-killing payload.

These treatments can produce important responses but may also cause organ-specific side effects. Eligibility depends on validated testing, prior therapy, regulatory approval, and the patient’s condition.

Clinical Trials

Professor Shen has led influential clinical trials in gastrointestinal oncology, including studies of immunotherapy, HER2-directed treatment, CLDN18.2-targeted approaches, and new combinations.

Clinical-trial participation requires strict eligibility. A matching diagnosis or biomarker does not guarantee enrollment. Trial location, treatment phase, required washout periods, organ function, prior therapies, and available places all matter.

Who May Consider a Consultation?

A consultation with Professor Shen or the Peking University Cancer Hospital gastrointestinal oncology team may be worth considering when a patient:

  • has advanced or recurrent gastric, esophageal, or colorectal cancer;
  • needs a second opinion on first-line or later-line treatment;
  • has a rare biomarker or conflicting molecular results;
  • has progressed after chemotherapy, targeted therapy, or immunotherapy;
  • needs pathology and molecular re-review;
  • wants to assess potential clinical-trial options;
  • has treatment toxicity requiring a revised strategy; or
  • needs multidisciplinary review of systemic and local treatment.

Medical Records to Prepare

International patients should prepare:

  • a concise medical summary and exact treatment timeline;
  • CT, MRI, PET-CT, and endoscopy images in original format;
  • pathology reports, glass slides, and paraffin blocks;
  • HER2, PD-L1, mismatch repair, microsatellite instability, CLDN18.2, RAS, BRAF, and sequencing reports when relevant;
  • operative and radiotherapy records;
  • every systemic treatment with dates, doses, response, and toxicity;
  • recent blood count, liver and kidney function, and tumor markers;
  • current symptoms and performance status;
  • a complete medication list; and
  • a clear list of questions and treatment priorities.

For clinical-trial review, include complete prior-treatment records and the most recent measurable-disease imaging.

Planning an International Consultation

Before traveling, patients should confirm whether records, pathology, and molecular results can be reviewed, whether an in-person examination is required, and whether additional testing is needed.

Remote medical-record review is subject to physician authorization. It may help clarify the next step, but final treatment and clinical-trial eligibility require complete assessment by the treating team.

How CMCS Can Assist

CMCS – China Medical Concierge Shanghai is an independent medical concierge and health management company, not a hospital. We assist international patients with organizing and translating oncology records, imaging, pathology, and molecular reports; identifying an appropriate specialist; requesting appointment availability; arranging interpretation; and planning medical travel in China.

Access to Professor Shen, remote review, targeted therapy, immunotherapy, or clinical trials is subject to the doctor’s and hospital’s approval. CMCS does not guarantee appointments, treatment eligibility, trial enrollment, or clinical outcomes.

For assistance, contact CMCS:

Important Note

Doctor titles, clinical roles, biomarker requirements, medicine approvals, trial availability, and appointment arrangements may change. Patients should confirm current information before travel. This profile is based on publicly available hospital and academic sources and is provided for general information only. It is not individual medical advice and does not replace assessment by a qualified oncology team.

0件のコメント

コメントを残す